A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease
Conclusion: The results of this trial indicate that the test drug (Fuke Qianjin capsule) is non-inferior to the control drug (doxycycline hyclate tablet) in treating mild-to-moderate PID patients with comparable efficacy, safety, and tolerability to the control drug.Clinical Trial Registration:www.clinicaltrials.gov, identifier NCT04723069.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: China Health | Chronic Pain | Clinical Trials | Complementary Medicine | Doxycycline | Drugs & Pharmacology | Electrocardiogram | Herbs | Laboratory Medicine | Metronidazole | Pain | Pakistan Health | Statistics | Ultrasound